← All trials
NCT03590171
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2017
- Primary completion
- Aug 31, 2023
- Completion date
- Aug 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 250
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Humboldt UniversityLead sponsor
- Humboldt UniversityOverall official - principal investigator
- Australian & New Zealand Childhood Hematology & Oncology GroupCollaborator
- University of ManchesterCollaborator
- University of Nice Sophia AntipolisCollaborator
- University of CopenhagenCollaborator
- EORTC Lung Cancer Cooperative GroupCollaborator
- Instituto Português de Oncologia de LisboaCollaborator
- Karolinska InstituteCollaborator
- Wroclaw Medical UniversityCollaborator
- University of OsloCollaborator
- Bambino Gesù Hospital and Research InstituteCollaborator
- Our Lady's Chilrden's Hospital, IrelandCollaborator
- Prinses Máxima CentrumCollaborator
- Spanish Society of Pediatric Hematology and OncologyCollaborator
- St. Anna KinderkrebsforschungCollaborator
- Tel Aviv UniversityCollaborator
- University of TurkuCollaborator
- University of ZurichCollaborator
- Charles UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.